Background: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia which increases the risk of thromboembolic complications and impairs quality of life. An important part of a therapeutic approach for AF is sinus rhythm restoration. Antiarrhythmic agents used in pharmacological cardioversion have limited efficacy and potential risk of proarrhythmia. Simultaneously, underlying conditions of AF should be treated (e.g. electrolyte imbalance, increased blood pressure, neurohormonal disturbances, atrial volume overload). There is still the need for an effective and safe approach to increase AF cardioversion efficacy. This randomized, double-blind, placebo-controlled, superiority clinical study is performed in patients with AF in order to evaluate the clinical efficacy of intravenous canrenone in sinus rhythm restoration. Methods: Eighty eligible patients with an episode of AF lasting less than 48 h are randomized in a 1:1 ratio to receive canrenone or placebo. Patients randomized to a treatment intervention are receiving canrenone intravenously at a dose of 200 mg within 2–3 min. Subjects assigned to a control group obtain the same volume of 0.9% saline within the same time. The primary endpoint includes return of sinus rhythm documented in the electrocardiogram within 2 h after drug or placebo administration. Other endpoints and safety outcomes analyses, due to expected lack of statistical power, are exploratory. Discussion: Current evidence supports renin–angiotensin–aldosterone system (RAAS) inhibition as an upstream therapy in AF management. Excess aldosterone secretion results in proarrhythmic effects. Among the RAAS inhibitors, only canrenone is administered intravenously. Canrenone additionally increases the plasma level of potassium, lowers blood pressure and reduces preload. It has been already used in primary and secondary hyperaldosteronism in the course of chronic liver dysfunction and in heart failure. Trial registration: ClinicalTrials.gov, NCT03536806. Registered on 25 May 2018.
There has been only moderate progress in our understanding of potential relation between atrial arrhythmia and stroke over years. Current approach is still based on a hypothesis that atrial contractile dysfunction due to fibrillation causes blood stasis, which accompanied by other factors acting together as Virchow’s triad produces thrombus and embolism to the brain. In this review we would like to discuss a relatively new concept of atrial cardiopathy. It assumes that risk of thromboembolism is increased regardless of atrial rhythm, being largely driven by atrial tissue abnormalities, such as fibrosis, endothelial and myocytes dysfunction and atrial dilatation. In this perspective AF may be a potential warning sign but not always a cause of thromboembolism. Atrial cardiopathy may cause thromboembolism even in the absence of AF and this approach is more neurologically-oriented. Another emerging issue is atrial cardiomyopathy defined as “any complex of structural, architectural, contractile or electrophysiological changes affecting the atria with the potential to produce clinically relevant manifestation”. There has been only moderate progress in our understanding of potential relation between atrial arrhythmia and stroke over years. Current approach is still based on a hypothesis that atrial contractile dysfunction due to fibrillation causes blood stasis, which accompanied by other factors acting together as Virchow’s triad produces thrombus and embolism to the brain. In this review we would like to discuss a relatively new concept of atrial cardiopathy. It assumes that risk of thromboembolism is increased regardless of atrial rhythm, being largely driven by atrial tissue abnormalities, such as fibrosis, endothelial and myocytes dysfunction and atrial dilatation. In this perspective AF may be a potential warning sign but not always a cause of thromboembolism. Atrial cardiopathy may cause thromboembolism even in the absence of AF and this approach is more neurologically-oriented. Another emerging issue is atrial cardiomyopathy defined as “any complex of structural, architectural, contractile or electrophysiological changes affecting the atria with the potential to produce clinically relevant manifestation”.
Justyna Mączyńska et al., Papillary fibroelastoma as a rare cause of recurrent strokes and myocardial infarction with PFE as one of the most common, we should remember the importance of a wide diagnostic approach when determining the cause of thromboembolic events, especially in cases of negative workup [4]. Secondary prevention with acetylsalicylic acid, P2Y 12 inhibitors, or VKA/direct oral anticoagulants might not always be sufficient.